shutterstock_1653845269_taljat_david
Taljat David / Shutterstock.com
4 May 2021AmericasMuireann Bolger

Novartis withdraws bid to block US Regeneron imports

Pharmaceutical company Novartis has abandoned its attempt to halt US imports of Regeneron’s Eylea pre-filled syringes amid concerns that such a ban could hinder public access to essential treatments.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
3 February 2022   Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.
Big Pharma
7 March 2022   Regeneron has failed to convince a Manhattan district court to drop a lawsuit claiming that it developed COVID-19 treatments using Allele’s fluorescent protein invention without its permission.
Big Pharma
19 April 2022   In a victory for Novartis, the Delhi High Court in India has issued a permanent injunction against two India-based companies which had allegedly sought to make a generic version of the Hepatitis C treatment, Revolade.

More on this story

Americas
3 February 2022   Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.
Big Pharma
7 March 2022   Regeneron has failed to convince a Manhattan district court to drop a lawsuit claiming that it developed COVID-19 treatments using Allele’s fluorescent protein invention without its permission.
Big Pharma
19 April 2022   In a victory for Novartis, the Delhi High Court in India has issued a permanent injunction against two India-based companies which had allegedly sought to make a generic version of the Hepatitis C treatment, Revolade.

More on this story

Americas
3 February 2022   Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.
Big Pharma
7 March 2022   Regeneron has failed to convince a Manhattan district court to drop a lawsuit claiming that it developed COVID-19 treatments using Allele’s fluorescent protein invention without its permission.
Big Pharma
19 April 2022   In a victory for Novartis, the Delhi High Court in India has issued a permanent injunction against two India-based companies which had allegedly sought to make a generic version of the Hepatitis C treatment, Revolade.